| LBCTR2019010183 | CLBH589D2222 | A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents | “A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents” | Interventional | Complete | 12/11/2018 |
| LBCTR2020094566 | FGCL-3019-095 | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | Interventional | Pending | 01/03/2021 |
| LBCTR2020104612 | BIO-2019-0257 | Impact of Phosphorus Ingestion with Fructose and Glucose on Substrate Utilization in Active Individuals During Moderate Exercise | Impact of Phosphorus Ingestion with Fructose and Glucose on Substrate Utilization in Active Individuals During Moderate Exercise | Interventional | Pending | 08/10/2020 |
| LBCTR2021014651 | 000000 | Managing Endothelial Dysfunction in COVID-19: A Randomized Clinical Trial at the Lebanese American University Medical Center- Rizk Hospital | Managing Endothelial Dysfunction in COVID-19: A Randomized Clinical Trial at the Lebanese American University Medical Center- Rizk Hospital | Interventional | Pending | 07/02/2021 |
| LBCTR2020043495 | Solidarity-Lebanon2020 | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | Interventional | Pending | 22/04/2020 |
| LBCTR2020124661 | 56021927PCR3015 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | Interventional | Pending | 06/11/2020 |
| LBCTR2020124677 | DCR-PHXC-301 | Long Term Extension Study in Patients With Primary Hyperoxaluria | An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria | Interventional | Other | 02/12/2020 |
| LBCTR2020124680 | LAU.SOP.ER2. 30/Sep/2019. | Value of pharmacy services upon admission to an orthopedic surgery unit | Value of pharmacy services upon admission to an orthopedic surgery unit | Interventional | Complete | 09/12/2020 |
| LBCTR2020011380 | CINC424A2X01B | Rollover An Open Label, Multi-center, Phase IV Rollover Protocol for Patients Who Have Completed a Global Novartis or Incyte Sponsored Ruxolitinib (INC424) or Ruxolitinib and Panobinostat (LBH589) Combination Study and Are Judged by the Investigator to Benefit From Continued Treatment | An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to benefit from continued treatment | Interventional | Complete | 02/01/2020 |
| LBCTR2019121369 | CLDK378A2112 | ASCEND 8-Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | Interventional | Complete | 27/12/2019 |